Lactic acidosis in diabetic population: Is metformin implicated? Results of a matched case-control study performed on the type 2 diabetes population of Grenoble Hospital University

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Lepelley, Marion ^a   Giai, Joris ^b,c   Yahiaoui, Nassima ^a   Chanoine, Sébastien ^a,d   Villier, Céline ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^d UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIRETROVIRUS AGENT; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; LACTIC ACID; METFORMIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ACUTE RESPIRATORY FAILURE; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; SEPSIS; ACIDOSIS, LACTIC; ACUTE KIDNEY INJURY; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; FRANCE; MIDDLE AGED; RISK ASSESSMENT; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VERY ELDERLY;

ACIDOSIS, LACTIC; ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; BIOMARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; HYPOGLYCEMIC AGENTS; LACTIC ACID; MALE; METFORMIN; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84962231504     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/3545914     Document Type: Article

References (27)

1. L. Guariguata, D. R. Whiting, I. Hambleton, J. Beagley, U. Linnenkamp, and J. E. Shaw, "Global estimates of diabetes prevalence for 2013 and projections for 2035, " Diabetes Research and Clinical Practice, vol. 103, no. 2, pp. 137-149, 2014.
2. Haute Autorite de Sante-Strategie medicamenteuse du controle glycemique du diabete de type 2 Aout, 2015 http://www . has-sante. fr/portail/jcms/c 1022476/fr/strategie-medicamenteuse-du-controle-glycemique-du-diabete-de-type-2.
3. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al. , "Managementof hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), " Diabetologia, vol. 55, no. 6, pp. 1577-1596, 2012.
4. R. C. Turner, C. A. Cull, V. Frighi, and R. R. Holman, "Glycemic controlwith diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49), " The Journal of the American Medical Association, vol. 281, no. 21, pp. 2005-2012, 1999.
5. J.-D. Lalau, "Lactic acidosis induced by metformin: incidence, management and prevention, " Drug Safety, vol. 33, no. 9, pp. 727-740, 2010.
6. V. Biradar, J. L. Moran, S. L. Peake, and J. V. Peter, "Metforminassociated lactic acidosis (MALA): clinical profile and outcomes in patients admitted to the intensive care unit, " Critical Care and Resuscitation, vol. 12, no. 3, pp. 191-195, 2010.
7. S. Salpeter, E. Greyber, G. Pasternak, and E. Salpeter, "Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus, " Cochrane Database of Systematic Reviews, no. 4, Article ID CD002967, 2010.
8. M. Bodmer, C. Meier, S. Krahenbuhl, S. S. Jick, and C. R. Meier, "Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis, " Diabetes Care, vol. 31, no. 11, pp. 2086-2091, 2008.
9. J.-D. Lalau and J.-M. Race, "Lactic acidosis in metformintreated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations, " Drug Safety, vol. 20, no. 4, pp. 377-384, 1999.
10. S. Vecchio and A. Protti, "Metformin-induced lactic acidosis: no one left behind, " Critical Care, vol. 15, no. 1, article 107, 2011.
11. I. R. F. van Berlo-van de Laar, C. G. Vermeij, and C. J. Doorenbos, "Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements, " Journal of Clinical Pharmacy andTherapeutics, vol. 36, no. 3, pp. 376-382, 2011.
12. T. A. Chowdhury, R. Wright, and M. M. Yaqoob, "Using metformin in the presence of renal disease, " The British Medical Journal, vol. 350, Article ID h1758, 2015.
13. A. T. Calabrese, K. C. Coley, S. V. DaPos, D. Swanson, and R. H. Rao, "Evaluation of prescribing practices: risk of lactic acidosis withmetformin therapy, " Archives of Internal Medicine, vol. 162, no. 4, pp. 434-437, 2002.
14. D. T. Eurich, F. A. McAlister, D. F. Blackburn et al. , "Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review, " British Medical Journal, vol. 335, no. 7618, pp. 497-501, 2007.
15. N. Papanas, E. Maltezos, and D. P. Mikhailidis, "Metformin and heart failure: never say never again, " Expert Opinion on Pharmacotherapy, vol. 13, no. 1, pp. 1-8, 2012.
16. K. P. Vasisht, S.-C. Chen, Y. Peng, and G. L. Bakris, "Limitations of metformin use in patients with kidney disease: are they warranted?" Diabetes, Obesity and Metabolism, vol. 12, no. 12, pp. 1079-1083, 2010.
17. W. E. Cayley Jr. , "Does metformin increase the risk of fatal or nonfatal lactic acidosis?"American Family Physician, vol. 82, no. 9, pp. 1068-1069, 2010.
18. A. Holstein, D. Nahrwold, S. Hinze, and E.-H. Egberts, "Contraindications to metformin therapy are largely disregarded, " Diabetic Medicine, vol. 16, no. 8, pp. 692-696, 1999.
19. R. D. Cohen and H. F. Woods, "Lactic acidosis revisited, " Diabetes, vol. 32, no. 2, pp. 181-191, 1983.
20. A. Emslie-Smith, D. I. R. Boyle, J. M. M. Evans, F. Sullivan, and A. D. Morris, "Contraindications to metformin therapy in patients with type 2 diabetes-a population-based study of adherence to prescribing guidelines, " DiabeticMedicine, vol. 18, no. 6, pp. 483-488, 2001.
21. K. J. Lipska, C. J. Bailey, and S. E. Inzucchi, "Use of metformin in the setting of mild-to-moderate renal insufficiency, " Diabetes Care, vol. 34, no. 6, pp. 1431-1437, 2011.
22. G. Sterner, S. Elmstahl, and A. Frid, "Renal function in a large cohort of metformin treated patients with type 2 diabetes mellitus, " British Journal of Diabetes and Vascular Disease, vol. 12, no. 5, pp. 227-231, 2012.
23. Type 2 Diabetes, 1-Recommendations, Guidance and Guidelines, August 2015, http://www. nice. org. uk/guidance/cg87/chapter/ 1-recommendations.
24. T. Scale and J. N. Harvey, "Diabetes, metformin and lactic acidosis, " Clinical Endocrinology, vol. 74, no. 2, pp. 191-196, 2011.
25. C. J. Girman, T. D. Kou, K. Brodovicz et al. , "Risk of acute renal failure in patients with Type 2 diabetes mellitus, " Diabetic Medicine, vol. 29, no. 5, pp. 614-621, 2012.
26. J. K. Duong, T. J. Furlong, D. M. Roberts et al. , "The role of metformin in metformin-associated lactic acidosis (MALA): case series and formulation of a model of pathogenesis, " Drug Safety, vol. 36, no. 9, pp. 733-746, 2013.
27. InVS-BEH no. 42-43, Diabete traite: quelles evolutions entre 2000 et 2009 en France ?, Disponible sur, 2010, http://www. invs . sante. fr/beh/2010/42 43/.